Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Novel anti-angiogenic PEDF-derived small peptides mitigate choroidal neovascularization.

Sheibani N, Wang S, Darjatmoko SR, Fisk DL, Shahi PK, Pattnaik BR, Sorenson CM, Bhowmick R, Volpert OV, Albert DM, Melgar-Asensio I, Henkin J.

Exp Eye Res. 2019 Sep 11;188:107798. doi: 10.1016/j.exer.2019.107798. [Epub ahead of print]

PMID:
31520600
2.

Apigenin Inhibits UVB-Induced Skin Carcinogenesis: The Role of Thrombospondin-1 as an Anti-Inflammatory Factor.

Mirzoeva S, Tong X, Bridgeman BB, Plebanek MP, Volpert OV.

Neoplasia. 2018 Sep;20(9):930-942. doi: 10.1016/j.neo.2018.07.005. Epub 2018 Aug 15.

3.

Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche.

Plebanek MP, Angeloni NL, Vinokour E, Li J, Henkin A, Martinez-Marin D, Filleur S, Bhowmick R, Henkin J, Miller SD, Ifergan I, Lee Y, Osman I, Thaxton CS, Volpert OV.

Nat Commun. 2017 Nov 6;8(1):1319. doi: 10.1038/s41467-017-01433-3.

4.

PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro.

Martinez-Marin D, Jarvis C, Nelius T, de Riese W, Volpert OV, Filleur S.

PLoS One. 2017 Apr 12;12(4):e0174968. doi: 10.1371/journal.pone.0174968. eCollection 2017.

5.

Pathways for Modulating Exosome Lipids Identified By High-Density Lipoprotein-Like Nanoparticle Binding to Scavenger Receptor Type B-1.

Angeloni NL, McMahon KM, Swaminathan S, Plebanek MP, Osman I, Volpert OV, Thaxton CS.

Sci Rep. 2016 Mar 11;6:22915. doi: 10.1038/srep22915.

6.

Melanoma Cells Block PEDF Production in Fibroblasts to Induce the Tumor-Promoting Phenotype of Cancer-Associated Fibroblasts.

Nwani NG, Deguiz ML, Jimenez B, Vinokour E, Dubrovskyi O, Ugolkov A, Mazar AP, Volpert OV.

Cancer Res. 2016 Apr 15;76(8):2265-76. doi: 10.1158/0008-5472.CAN-15-2468. Epub 2016 Feb 26.

7.

Inhibition of mTOR by apigenin in UVB-irradiated keratinocytes: A new implication of skin cancer prevention.

Bridgeman BB, Wang P, Ye B, Pelling JC, Volpert OV, Tong X.

Cell Signal. 2016 May;28(5):460-468. doi: 10.1016/j.cellsig.2016.02.008. Epub 2016 Feb 12.

8.

Therapeutic manipulation of angiogenesis with miR-27b.

Veliceasa D, Biyashev D, Qin G, Misener S, Mackie AR, Kishore R, Volpert OV.

Vasc Cell. 2015 Jun 24;7:6. doi: 10.1186/s13221-015-0031-1. eCollection 2015.

9.

Chemopreventive apigenin controls UVB-induced cutaneous proliferation and angiogenesis through HuR and thrombospondin-1.

Tong X, Mirzoeva S, Veliceasa D, Bridgeman BB, Fitchev P, Cornwell ML, Crawford SE, Pelling JC, Volpert OV.

Oncotarget. 2014 Nov 30;5(22):11413-27.

10.

High Density Lipoprotein Nanoparticles Deliver RNAi to Endothelial Cells to Inhibit Angiogenesis.

Tripathy S, Vinokour E, McMahon KM, Volpert OV, Thaxton CS.

Part Part Syst Charact. 2014 Nov 1;31(11):1141-1150.

11.

miR-200b inhibits prostate cancer EMT, growth and metastasis.

Williams LV, Veliceasa D, Vinokour E, Volpert OV.

PLoS One. 2013 Dec 31;8(12):e83991. doi: 10.1371/journal.pone.0083991. eCollection 2013.

12.

The many facets of PEDF in drug discovery and disease: a diamond in the rough or split personality disorder?

Craword SE, Fitchev P, Veliceasa D, Volpert OV.

Expert Opin Drug Discov. 2013 Jul;8(7):769-92. doi: 10.1517/17460441.2013.794781. Epub 2013 May 6. Review.

PMID:
23642051
13.

Snf1-related kinase inhibits colon cancer cell proliferation through calcyclin-binding protein-dependent reduction of β-catenin.

Rines AK, Burke MA, Fernandez RP, Volpert OV, Ardehali H.

FASEB J. 2012 Nov;26(11):4685-95. doi: 10.1096/fj.12-212282. Epub 2012 Aug 8.

14.

Androgen receptor drives cellular senescence.

Mirochnik Y, Veliceasa D, Williams L, Maxwell K, Yemelyanov A, Budunova I, Volpert OV.

PLoS One. 2012;7(3):e31052. doi: 10.1371/journal.pone.0031052. Epub 2012 Mar 5.

15.

miR-27b controls venous specification and tip cell fate.

Biyashev D, Veliceasa D, Topczewski J, Topczewska JM, Mizgirev I, Vinokour E, Reddi AL, Licht JD, Revskoy SY, Volpert OV.

Blood. 2012 Mar 15;119(11):2679-87. doi: 10.1182/blood-2011-07-370635. Epub 2011 Dec 29.

16.

Therapies using anti-angiogenic peptide mimetics of thrombospondin-1.

Henkin J, Volpert OV.

Expert Opin Ther Targets. 2011 Dec;15(12):1369-86. doi: 10.1517/14728222.2011.640319. Epub 2011 Dec 5. Review.

PMID:
22136063
17.

p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers.

Sundaram P, Hultine S, Smith LM, Dews M, Fox JL, Biyashev D, Schelter JM, Huang Q, Cleary MA, Volpert OV, Thomas-Tikhonenko A.

Cancer Res. 2011 Dec 15;71(24):7490-501. doi: 10.1158/0008-5472.CAN-11-1124. Epub 2011 Oct 25.

18.

Pigment epithelium-derived factor blocks tumor extravasation by suppressing amoeboid morphology and mesenchymal proteolysis.

Ladhani O, Sánchez-Martinez C, Orgaz JL, Jimenez B, Volpert OV.

Neoplasia. 2011 Jul;13(7):633-42.

19.

Changes in the gene expression profile of A375 human melanoma cells induced by overexpression of multifunctional pigment epithelium-derived factor.

Orgaz JL, Benguria A, Sanchez-Martinez C, Ladhani O, Volpert OV, Jimenez B.

Melanoma Res. 2011 Aug;21(4):285-97. doi: 10.1097/CMR.0b013e32834495c3.

20.

Sonic hedgehog induces angiogenesis via Rho kinase-dependent signaling in endothelial cells.

Renault MA, Roncalli J, Tongers J, Thorne T, Klyachko E, Misener S, Volpert OV, Mehta S, Burg A, Luedemann C, Qin G, Kishore R, Losordo DW.

J Mol Cell Cardiol. 2010 Sep;49(3):490-8. doi: 10.1016/j.yjmcc.2010.05.003. Epub 2010 May 15.

21.

NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement.

Aurora AB, Biyashev D, Mirochnik Y, Zaichuk TA, Sánchez-Martinez C, Renault MA, Losordo D, Volpert OV.

Blood. 2010 Jul 22;116(3):475-84. doi: 10.1182/blood-2009-07-232132. Epub 2010 Mar 4. Erratum in: Blood. 2010 Dec 2;116(23):5079. Aurora, Aryn B [corrected to Aurora, Arin B].

22.

Natural angiogenesis inhibitor signals through Erk5 activation of peroxisome proliferator-activated receptor gamma (PPARgamma).

Biyashev D, Veliceasa D, Kwiatek A, Sutanto MM, Cohen RN, Volpert OV.

J Biol Chem. 2010 Apr 30;285(18):13517-24. doi: 10.1074/jbc.M110.117374. Epub 2010 Feb 25.

23.

'Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma'.

Orgaz JL, Ladhani O, Hoek KS, Fernández-Barral A, Mihic D, Aguilera O, Seftor EA, Bernad A, Rodríguez-Peralto JL, Hendrix MJ, Volpert OV, Jiménez B.

Oncogene. 2009 Nov 26;28(47):4147-61. doi: 10.1038/onc.2009.284. Epub 2009 Sep 21.

24.

Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth.

Mirochnik Y, Aurora A, Schulze-Hoepfner FT, Deabes A, Shifrin V, Beckmann R, Polsky C, Volpert OV.

Clin Cancer Res. 2009 Mar 1;15(5):1655-63. doi: 10.1158/1078-0432.CCR-08-2113. Epub 2009 Feb 17.

25.

PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments.

Veliceasa D, Schulze-Hoëpfner FT, Volpert OV.

PPAR Res. 2008;2008:945275. doi: 10.1155/2008/945275. Epub 2008 Nov 18.

26.

Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.

Mirochnik Y, Kwiatek A, Volpert OV.

Curr Drug Targets. 2008 Oct;9(10):851-62. Review.

27.

Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism.

Smith ND, Schulze-Hoepfner FT, Veliceasa D, Filleur S, Shareef S, Huang L, Huang XM, Volpert OV.

J Urol. 2008 Jun;179(6):2427-34. doi: 10.1016/j.juro.2008.01.081. Epub 2008 Apr 23.

28.

Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma.

Veliceasa D, Ivanovic M, Hoepfner FT, Thumbikat P, Volpert OV, Smith ND.

FEBS J. 2007 Dec;274(24):6365-77. Epub 2007 Nov 15.

29.

Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.

Nelius T, Filleur S, Yemelyanov A, Budunova I, Shroff E, Mirochnik Y, Aurora A, Veliceasa D, Xiao W, Wang Z, Volpert OV.

Int J Cancer. 2007 Sep 1;121(5):999-1008.

30.

Pigment epithelium-derived factor as a multifunctional antitumor factor.

Fernandez-Garcia NI, Volpert OV, Jimenez B.

J Mol Med (Berl). 2007 Jan;85(1):15-22. Epub 2006 Nov 15. Review.

PMID:
17106733
31.

MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis.

Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C, Jordan VC, Volpert OV, Satcher RL Jr, Gartenhaus RB.

Cancer Res. 2005 Dec 1;65(23):10651-6.

32.

Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.

Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV.

Clin Cancer Res. 2005 Sep 15;11(18):6678-85.

33.

Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer.

Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, Aymerich MS, Becerra SP, Yap R, Veliceasa D, Shroff EH, Volpert OV.

Cancer Res. 2005 Jun 15;65(12):5144-52.

34.

In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment.

Quesada AJ, Nelius T, Yap R, Zaichuk TA, Alfranca A, Filleur S, Volpert OV, Redondo JM.

Cell Death Differ. 2005 Jun;12(6):649-58.

35.

Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510.

Huang H, Campbell SC, Bedford DF, Nelius T, Veliceasa D, Shroff EH, Henkin J, Schneider A, Bouck N, Volpert OV.

Mol Cancer Res. 2004 Oct;2(10):541-50.

36.

Captopril suppresses post-transplantation angiogenic activity in rat allograft coronary vessels.

Crawford SE, Mavroudis C, Backer CL, Huang X, Mu Y, Volpert OV, Stellmach V, Pahl E, Huang L.

J Heart Lung Transplant. 2004 Jun;23(6):666-73.

PMID:
15366425
37.

Alpha1-antitrypsin inhibits angiogenesis and tumor growth.

Huang H, Campbell SC, Nelius T, Bedford DF, Veliceasa D, Bouck NP, Volpert OV.

Int J Cancer. 2004 Dec 20;112(6):1042-8.

38.

Nuclear factor of activated T cells balances angiogenesis activation and inhibition.

Zaichuk TA, Shroff EH, Emmanuel R, Filleur S, Nelius T, Volpert OV.

J Exp Med. 2004 Jun 7;199(11):1513-22.

39.

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

Zhang YW, Su Y, Volpert OV, Vande Woude GF.

Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12718-23. Epub 2003 Oct 10.

40.

Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase.

Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE.

Circ Res. 2003 Aug 22;93(4):321-9. Epub 2003 Jul 24.

PMID:
12881477
41.

Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1.

Volpert OV, Alani RM.

Cancer Cell. 2003 Mar;3(3):199-200.

42.

Cyclooxygenase-2: a therapeutic target in angiogenesis.

Iñiguez MA, Rodríguez A, Volpert OV, Fresno M, Redondo JM.

Trends Mol Med. 2003 Feb;9(2):73-8. Review.

PMID:
12615041
43.

SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis.

Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL.

Cancer Res. 2002 Dec 15;62(24):7357-63.

44.

Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1.

Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM.

Cancer Cell. 2002 Dec;2(6):473-83.

45.

Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor.

Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP.

Nat Med. 2002 Apr;8(4):349-57.

PMID:
11927940
46.

Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.

Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC.

Int J Cancer. 2002 Apr 10;98(5):682-9.

47.

Mechanistic insights on the inhibition of tumor angiogenesis.

Jiménez B, Volpert OV.

J Mol Med (Berl). 2001;78(12):663-72. Review.

PMID:
11434719
48.

c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.

Jiménez B, Volpert OV, Reiher F, Chang L, Muñoz A, Karin M, Bouck N.

Oncogene. 2001 Jun 7;20(26):3443-8.

49.

In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.

Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clézardin P, Bouck N, Cabon F.

Genes Dev. 2001 Jun 1;15(11):1373-82.

50.

Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2.

Hernández GL, Volpert OV, Iñiguez MA, Lorenzo E, Martínez-Martínez S, Grau R, Fresno M, Redondo JM.

J Exp Med. 2001 Mar 5;193(5):607-20.

Supplemental Content

Loading ...
Support Center